spike protein of SARS-Co V-2

GPTKB entity

Statements (68)
Predicate Object
gptkbp:instance_of gptkb:protein
gptkbp:bfsLayer 6
gptkbp:bfsParent gptkb:tixagevimab
gptkbp:code SARS-Co V-2 genome
gptkbp:combatants AC E2 receptor
gptkbp:composed_of amino acids
gptkbp:financial_performance glycosylation
gptkbp:function facilitates entry into host cells
gptkbp:has_variants gptkb:Delta_variant
Omicron variant
https://www.w3.org/2000/01/rdf-schema#label spike protein of SARS-Co V-2
gptkbp:is_aimed_at preventive measures
therapeutic interventions
vaccines
monoclonal antibodies
therapeutics
neutralizing antibodies
vaccine candidates
broadly neutralizing antibodies
gptkbp:is_analyzed_in structural stability
structural biology studies
mutation effects
antigenic properties
gptkbp:is_associated_with immune evasion
gptkbp:is_characterized_by S1 and S2 subunits
glycoprotein structure
receptor binding domain
gptkbp:is_critical_for viral infectivity
gptkbp:is_involved_in antigen presentation
pathogen recognition
viral replication
host immune response
cellular signaling
viral pathogenesis
viral assembly
pathogen-host dynamics
antibody binding
cell membrane fusion
cellular entry pathways
host cell interaction
viral entry mechanism
viral fusion
gptkbp:is_linked_to vaccine efficacy
viral load
transmission dynamics
vaccine breakthrough infections
COVID-19 severity
gptkbp:is_part_of viral envelope
viral structure
viral glycoproteins
viral life cycle
gptkbp:is_represented_in gptkb:healthcare_organization
infected cells
vaccine-induced immunity
gptkbp:is_studied_in COVID-19 research
clinical trials
vaccine development
therapeutic antibodies
vaccine safety
immune response modulation
antiviral strategies
vaccine formulation
vaccine design
vaccine response assessment
gptkbp:is_used_in diagnostic assays
gptkbp:part_of gptkb:SARS-Co_V-2
gptkbp:recognizes serological tests
gptkbp:trigger_type immune response